Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ngm Biopharmaceuticals Inc (NQ: NGM ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ngm Biopharmaceuticals Inc < Previous 1 2 Next > NGM Bio Announces Closing of Tender Offer April 05, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting March 19, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM March 13, 2024 From Kahn Swick & Foti, LLC Via Business Wire NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results March 11, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM February 27, 2024 From Kahn Swick & Foti, LLC Via Business Wire NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders February 26, 2024 From Halper Sadeh LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT) February 26, 2024 From Brodsky & Smith LLC Via GlobeNewswire NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP February 26, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in the Cowen 44th Annual Health Care Conference February 20, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference January 17, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need January 09, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® November 13, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in Upcoming Investor Conferences November 07, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights November 02, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting® October 11, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights August 03, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in Upcoming Investor Conferences May 25, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023 May 08, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data May 04, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference March 01, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results February 28, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference January 12, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities January 09, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting December 12, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting December 07, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting November 07, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting November 04, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results November 03, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting November 03, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration October 17, 2022 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.